glp-1/glucagon dual receptor agonist Science Behind GLP 1 GIP and Glucagon Agonists for Obesity Research | News & Announcements GLP-1-based therapies for type 2

Patents are legal mechanisms designed to promote innovation by giving pharmaceutical companies exclusive rights to sell their drugs without competition for a specified period (usually 17 and a half years)

Given the high unmet medical need, limited competition, and established efficacy in narcolepsy, WAKIX is expected to gain strong commercial traction and have an extended market uptake period if approved for PWS

Compounded semaglutide is considered an eligible medical expense when prescribed by a licensed provider for a diagnosed medical condition (obesity or type 2 diabetes)

They stimulate the pancreas to release more insulin, suppress the glucagon hormone, working together as a replacement for the GLP-1 hormone to control blood sugar levels in people with type 2 diabetes

doi: 10.1111/dom.12932 [DOI] [PMC free article] [PubMed] [Google Scholar] 241

Were a passionate team obsessed with quality, not margins